ALLERGY THERAPEUTICS PLC

Share Issue/Capital Change • Jan 22, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0842W

Allergy Therapeutics PLC

22 January 2013

22 January 2013

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Exercise of Options

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 23,850 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 25 January 2013. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company.

The total number of shares in issue (inclusive of the above issue) is 409,866,831 Ordinary shares of 0.1p each.

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	+44 (0) 207 776 1200
Juliet Thompson / Clare Terlouw
FTI Consulting	+44 (0) 207 831 3113
Simon Conway / Susan Stuart / Victoria Foster Mitchell

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAEFAADNDEFF